All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?
Featured
Bookmark this article
During the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE. We asked, What is the latest data from REACH-3 for ruxolitinib treated patients with steroid refractory chronic graft versus host disease (SR-cGvHD) after crossover?
What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?
Zeiser begins by explaining the motivation behind REACH-3 and goes on to outline its study design. He then provides insights on the efficacy and tolerability data presented at the 49th Annual Meeting of the EBMT, including response rates and comparisons with existing safety profiles. Zeiser concludes by detailing the applications of ruxolitinib in patients with steroid refractory chronic GvHD who have not responded to other systemic therapies.
More information on the REACH-3 clinical trial can be found on the GvHD Hub, here.
Your opinion matters
8 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox